Pharmsynthez Share Price

LIFE

RU000A0JR514

Pharmaceuticals

End-of-day quote Moscow Micex - RTS Other stock markets 08/07/2022			5-day change	1st Jan Change
4.505 ^RUB	+10.15%		-.--%	-

02/06	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Farmsintez PAO (Farmsintez OJSC) is a Russia-based company, which is engaged in the pharmaceutical sector. The Company focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The Company sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. It has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Companyâ€™s major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
LIFE Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	135.61Cr 11TCr 119.01Cr 110.82Cr 101.93Cr 191.07Cr 13TCr 194.35Cr 1.31TCr 514.61Cr 6.42TCr 509.09Cr 498.09Cr 22TCr	P/E 2021	-2.42x	P/E 2022	-6.53x
Enterprise Value	209.23Cr 16TCr 183.62Cr 170.99Cr 157.27Cr 294.81Cr 20TCr 299.87Cr 2.03TCr 794Cr 9.91TCr 785.49Cr 768.52Cr 34TCr	EV / Sales 2021	5.43x	EV / Sales 2022	5.51x
Free-Float	95.22%	Yield 2021 *	-	Yield 2022	-

02/06	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025	CI
27/11	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
29/25/29	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2025	CI
28/23/28	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2023	CI
19/23/19	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
19/23/19	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022	CI
08/22/08	Public Joint-Stock Company "Pharmsynthez" announced that it expects to receive funding from Central Bank of the Russian Federation	CI
28/22/28	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
12/21/12	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2021	CI
16/21/16	Xenetic Biosciences, Inc. Enters into Amendment Number One to Master Services Agreement with PJSC Pharmsynthez	CI
14/21/14	Market Chatter: South Korean Regulator Rejects Thelma Therapeutics's Phase Three Trial for COVID-19 Cure	MT
02/21/02	Public Joint-Stock Company Pharmsynthez Reports Earnings Results for the Full Year Ended December 31, 2018	CI

5 years	2.64		7
10 years	2.64		18.75

Manager	Title	Age	Since
Petr Vladimirovich Kruglyakov CEO	Chief Executive Officer	48	01/01/2014
Alexey Shafranov DFI	Director of Finance/CFO	47	-
Dmitriy Nikolayevich Poznyak CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dmitriy Genkin CHM	Chairman	57	01/01/2005
Indrek Kasela BRD	Director/Board Member	54	01/01/2007
Steve Gorelik BRD	Director/Board Member	47	01/01/2007

Pharmsynthez Share Price

Stocks

LIFE

RU000A0JR514

Pharmaceuticals

Valuation: Pharmsynthez

Latest news : Pharmsynthez

Quotes and Performance

Course Extremes

Managers and Directors: Pharmsynthez

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHARMSYNTHEZ	+10.15%	-.--%	-.--%	-.--%	2.53Cr
ELI LILLY AND COMPANY	+1.93%	+3.85%	+51.05%	+166.24%	1,08900Cr
JOHNSON & JOHNSON	+0.29%	+6.43%	+60.47%	+52.87%	64TCr
ABBVIE INC.	+2.45%	+2.77%	+39.61%	+74.48%	47TCr
ROCHE HOLDING AG	+0.12%	+11.19%	+42.43%	+36.59%	36TCr
NOVARTIS AG	+0.68%	+4.71%	+38.56%	+44.11%	30TCr
ASTRAZENECA PLC	+1.31%	+2.87%	+17.10%	+16.81%	27TCr
NOVO NORDISK A/S	-0.45%	+4.19%	-4.04%	-39.04%	23TCr
AMGEN INC.	+4.48%	+7.33%	+30.47%	+66.31%	21TCr
GILEAD SCIENCES, INC.	+2.91%	+3.10%	+18.84%	+74.76%	17TCr
Average	+2.46%	+5.58%	+29.45%	+49.31%	37.31TCr
Weighted average by Cap.	+1.57%	+5.14%	+41.02%	+79.95%

	2021	2022
Net sales	44Cr 3.45TCr 38Cr 36Cr 33Cr 62Cr 4.19TCr 63Cr 424.98Cr 166.34Cr 2.08TCr 164.56Cr 161Cr 7.18TCr	38Cr 2.99TCr 33Cr 31Cr 29Cr 53Cr 3.63TCr 54Cr 368.1Cr 144.08Cr 1.8TCr 142.54Cr 139.46Cr 6.22TCr
Net income	-70Cr -5.49TCr -61Cr -57Cr -52Cr -98Cr -6.66TCr -100Cr -676.3Cr -264.71Cr -3.3TCr -261.87Cr -256.22Cr -11TCr	-21Cr -1.63TCr -18Cr -17Cr -16Cr -29Cr -1.98TCr -30Cr -201.17Cr -79Cr -983.1Cr -78Cr -76Cr -3.4TCr
Net Debt	69Cr 5.46TCr 61Cr 57Cr 52Cr 98Cr 6.62TCr 99Cr 671.8Cr 262.95Cr 3.28TCr 260.13Cr 254.51Cr 11TCr	74Cr 5.8TCr 65Cr 60Cr 55Cr 103.74Cr 7.03TCr 105.52Cr 713.8Cr 279.39Cr 3.49TCr 276.4Cr 270.43Cr 12TCr